The PI3Kα-specific inhibitor alpelisib (PIQRAY or BYL-719) recently obtained approval for PIK3CA-mutated hormone receptor-positive advanced breast cancer in combination with fulvestrant, a hormonotherapy [11]. The gene discussed is PIK3CA; the disease is breast carcinoma.